KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Evolent Health (EVH) EBITDA Margin (2016 - 2026)

Evolent Health has reported EBITDA Margin over the past 11 years, most recently at 91.61% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 8681.0% year-over-year to 91.61%; the TTM value through Dec 2025 reached 30.93%, down 2725.0%, while the annual FY2025 figure was 30.93%, 2725.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 91.61% at Evolent Health, down from 5.76% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 0.53% in Q3 2022 and troughed at 91.61% in Q4 2025.
  • A 5-year average of 9.51% and a median of 4.91% in 2024 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: soared 8953bps in 2021 and later crashed -8681bps in 2025.
  • Year by year, EBITDA Margin stood at 2.27% in 2021, then plummeted by -32bps to 3.0% in 2022, then crashed by -148bps to 7.44% in 2023, then skyrocketed by 36bps to 4.79% in 2024, then plummeted by -1811bps to 91.61% in 2025.
  • Business Quant data shows EBITDA Margin for EVH at 91.61% in Q4 2025, 5.76% in Q3 2025, and 11.49% in Q2 2025.